Report · Health

63% of Americans expect injectable weight-loss drugs to keep gaining users

Reading

In a Verasight survey conducted Aug. 1-6, 2025, nearly two-thirds of Americans (63%) expect the use of injectable weight-loss drugs like Ozempic to keep climbing beyond current levels.

About one-in-five (18%) do not, and a similar share (19%) are unsure.

Topline

single choice

Topline distribution

63% of Americans expect injectable weight-loss drugs to keep gaining users.

In your opinion, will the use of injectable weight loss drugs (like Ozempic) continue to grow, beyond it's current level of use?

  • Yes 63.1%
  • Don't know 19.0%
  • No 17.8%

2025 · base n 1,000 · +/- 3.2%

B

View source

Methodology

Full methodology
Mode
Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting
Field dates
2025-08-01 → 2025-08-06
Base (unweighted)
1,000
Margin of error
+/- 3.2%
Module
B

Source

Citation

Verasight Quirks Omnibus Survey, fielded August 1-6, 2025, N=1,000 United States adults, +/- 3.2%.

https://verasight-quirks-2025.tiiny.co

Verasight survey methodology

How Verasight conducts surveys.

This page describes the Verasight general survey contract, separate from how the Data Library packages it. When a wave report is published, its field dates, sample sizes, and module breakdown are listed in that report.

Mode
Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting.
Population
US adults age 18+.
Sample design
Surveys are run as omnibus or single-topic waves. Omnibus waves are split into modules with their own respondent set, typically around one thousand respondents per module.
Field window
Each wave specifies its own field dates. Most omnibus waves field across roughly two weeks.
Weighting
Per-module weighting to CPS targets including age, race and ethnicity, sex, income, education, region, and metropolitan status.
Partisanship benchmark
Pew Research Center's NPORS benchmarking surveys, three-year running average.
Vote benchmark
2024 presidential vote population benchmarks.
Margin of error
Typically about plus or minus 3.4 to 3.6 percent per module at standard module sizes. Question-level MoE is recomputed when a base shrinks materially below the module baseline.
Reporting
The canonical report hub is reports.verasight.io. Verified legacy reports remain on their original hosts, and unpublished reports are marked pending.
Transparency
Verasight is a member of the American Association for Public Opinion Research Transparency Initiative.

The canonical report hub is reports.verasight.io; older reports may remain on verified legacy hosts.